The head of the Gamaleya Research Center for Epidemiology and Microbiology, Alexander Gintsburg, announced the universality of the Sputnik V vaccine in the fight against all types of coronavirus infection. His words on June 21 are quoted by RIA Novosti.
“Due to the infinite number of genetic variants that have clinically significant manifestations, the Sputnik V vaccine acts in this case as a universal vaccine against all of these variants,” – said the interlocutor of the agency on the sidelines of the St. Petersburg International Economic Forum (SPIEF).
In addition, Gunzburg recalled the need to continue to be vaccinated against COVID-19. This is important, he says, because people with antibodies don’t always have the right levels of neutralizing antibodies.
The day before, the head of the Gamaleya Research Center for Epidemiology and Microbiology called the introduction of coronavirus vaccination into the national vaccination calendar as a way to solve problems with the spread of COVID-19. The Gamaleya Institute has created a vaccine for all populations, except for children aged 0-6 so far, he said.
At the same time, as he noted earlier, on June 15, as part of clinical studies of children aged 9–11 years, no significant side effects were noted in those who received the coronavirus vaccine.
Currently, clinical trials of a coronavirus vaccine developed by the Gamaleya Center are ongoing. They are carried out among children from 6 to 11 years. In January, Gunzburg reported that research could take up to 3.5 months.
The vaccination campaign continues in Russia. Citizens are vaccinated for free. Seven drugs against coronavirus have been registered in the country: the world’s first COVID-19 vaccine Sputnik V, Sputnik Light, Sputnik M, EpiVacCorona, EpiVacCorona-N, CoviVac and Convasel.
All up-to-date information on the situation with coronavirus is available on the sites stopcoronavirus.rf and access to everyone.rf, as well as on the hashtag #WeTogether. Coronavirus hotline: 8 (800) 2000-112.